{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:46:20Z","timestamp":1750999580770},"reference-count":32,"publisher":"Japanese Society of Toxicology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2023]]},"DOI":"10.2131\/jts.48.191","type":"journal-article","created":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T22:12:36Z","timestamp":1680473556000},"page":"191-202","source":"Crossref","is-referenced-by-count":2,"title":["Toxicity manifestations and sex differences due to MARTA olanzapine"],"prefix":"10.2131","volume":"48","author":[{"given":"Natsumi","family":"Hattori-Usami","sequence":"first","affiliation":[{"name":"Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy"},{"name":"Showa University Pharmacological Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Kaizaki-Mitsumoto","sequence":"additional","affiliation":[{"name":"Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy"},{"name":"Showa University Pharmacological Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ashino","sequence":"additional","affiliation":[{"name":"Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy"},{"name":"Showa University Pharmacological Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Numazawa","sequence":"additional","affiliation":[{"name":"Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy"},{"name":"Showa University Pharmacological Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Abraham, N.G. and Kappas, A. (2008): Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev., <b>60<\/b>, 79-127.","DOI":"10.1124\/pr.107.07104"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Albaugh, V.L., Henry, C.R., Bello, N.T., Hajnal, A., Lynch, S.L., Halle, B. and Lynch, C.J. (2006): Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring), <b>14<\/b>, 36-51.","DOI":"10.1038\/oby.2006.6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Buckley, D.B. and Klaassen, C.D. (2007): Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab. Dispos., <b>35<\/b>, 121-127.","DOI":"10.1124\/dmd.106.012070"},{"key":"4","doi-asserted-by":"publisher","unstructured":"Bymaster, F.P., Calligaro, D.O., Falcone, J.F., Marsh, R.D., Moore, N.A., Tye, N.C., Seeman, P. and Wong, D.T. (1996): Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, <b>14<\/b>, 87-96.","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Choi, S., DiSilvio, B., Unangst, J. and Fernstrom, J.D. (2007): Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci., <b>81<\/b>, 1024-1030.","DOI":"10.1016\/j.lfs.2007.08.009"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Davoodi, N., Kalinichev, M., Korneev, S.A. and Clifton, P.G. (2009): Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl.), <b>203<\/b>, 693-702.","DOI":"10.1007\/s00213-008-1415-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Diaz, A., Lopez-Grueso, R., Gambini, J., Monleon, D., Mas-Bargues, C., Abdelaziz, K.M., Vina, J. and Borras, C. (2019): Sex differences in age-associated type 2 diabetes in rats\u2014role of estrogens and oxidative stress. Oxid. Med. Cell. Longev., <b>2019<\/b>, 6734836.","DOI":"10.1155\/2019\/6734836"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Ebenbichler, C.F., Laimer, M., Eder, U., Mangweth, B., Weiss, E., Hofer, A., Hummer, M., Kemmler, G., Lechleitner, M., Patsch, J.R. and Fleischhacker, W.W. (2003): Olanzapine induces insulin resistance: results from a prospective study. J. Clin. Psychiatry, <b>64<\/b>, 1436-1439.","DOI":"10.4088\/JCP.v64n1206"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Franklin, C.C., Backos, D.S., Mohar, I., White, C.C., Forman, H.J. and Kavanagh, T.J. (2009): Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase. Mol. Aspects Med., <b>30<\/b>, 86-98.","DOI":"10.1016\/j.mam.2008.08.009"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gardner, D.M., Baldessarini, R.J. and Waraich, P. (2005): Modern antipsychotic drugs: a critical overview. CMAJ, <b>172<\/b>, 1703-1711.","DOI":"10.1503\/cmaj.1041064"},{"key":"11","first-page":"6","author":"A.S. Go","year":"2013","unstructured":"Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., Bravata, D.M., Dai, S., Ford, E.S., Fox, C.S., Franco, S., Fullerton, H.J., Gillespie, C., Hailpern, S.M., Heit, J.A., Howard, V.J., Huffman, M.D., Kissela, B.M., Kittner, S.J., Lackland, D.T., Lichtman, J.H., Lisabeth, L.D., Magid, D., Marcus, G.M., Marelli, A., Matchar, D.B., McGuire, D.K., Mohler, E.R., Moy, C.S., Mussolino, M.E., Nichol, G., Paynter, N.P., Schreiner, P.J., Sorlie, P.D., Stein, J., Turan, T.N., Virani, S.S., Wong, N.D., Woo, D. and Turner, M.B. (2013): Heart disease and stroke statistics-2013 update: A report from the american heart association. Circulation, <b>127<\/b>, 6-245.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Gourineni, V., Shay, N.F., Chung, S., Sandhu, A.K. and Gu, L. (2012): Muscadine grape (Vitis rotundifolia) and wine phytochemicals prevented obesity-associated metabolic complications in C57BL\/6J mice. J. Agric. Food Chem., <b>60<\/b>, 7674-7681.","DOI":"10.1021\/jf3013663"},{"key":"13","unstructured":"Haupt, D.W. and Newcomer, J.W. (2001): Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry, <b>62<\/b> (Suppl 27), 15-26, discussion, 40-41."},{"key":"14","doi-asserted-by":"crossref","unstructured":"Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M. and Nabeshima, Y. (1997): An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun., <b>236<\/b>, 313-322.","DOI":"10.1006\/bbrc.1997.6943"},{"key":"15","unstructured":"Kassahun, K., Mattiuz, E., Nyhart, E. Jr., Obermeyer, B., Gillespie, T., Murphy, A., Goodwin, R.M., Tupper, D., Callaghan, J.T. and Lemberger, L. (1997): Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos., <b>25<\/b>, 81-93."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Kluge, M., Schuld, A., Himmerich, H., Dalal, M., Schacht, A., Wehmeier, P.M., Hinze-Selch, D., Kraus, T., Dittmann, R.W. and Pollm\u00e4cher, T. (2007): Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J. Clin. Psychopharmacol., <b>27<\/b>, 662-666.","DOI":"10.1097\/jcp.0b013e31815a8872"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Li, P., Snyder, G.L. and Vanover, K.E. (2016): Dopamine targeting drugs for the treatment of schizophrenia: Past, present and future. Curr. Top. Med. Chem., <b>16<\/b>, 3385-3403.","DOI":"10.2174\/1568026616666160608084834"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Lord, C.C., Wyler, S.C., Wan, R., Castorena, C.M., Ahmed, N., Mathew, D., Lee, S., Liu, C. and Elmquist, J.K. (2017): The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J. Clin. Invest., <b>127<\/b>, 3402-3406.","DOI":"10.1172\/JCI93362"},{"key":"19","doi-asserted-by":"publisher","unstructured":"Low Wang, C.C., Hess, C.N., Hiatt, W.R. and Goldfine, A.B. (2016): Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes \u2013 mechanisms, management, and clinical considerations. Circulation, <b>133<\/b>, 2459-2502.","DOI":"10.1161\/CIRCULATIONAHA.116.022194"},{"key":"20","first-page":"1","author":"S. Ninagawa","year":"2020","unstructured":"Ninagawa, S., Tada, S., Okumura, M., Inoguchi, K., Kinoshita, M., Kanemura, S., Imami, K., Umezawa, H., Ishikawa, T., Mackin, R.B., Torii, S., Ishihama, Y., Inaba, K., Anazawa, T., Nagamine, T. and Mori, K. (2020): Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes. eLife, <b>9<\/b>, 1-26.","journal-title":"eLife","ISSN":"http:\/\/id.crossref.org\/issn\/2050-084X","issn-type":"print"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Pouzet, B., Mow, T., Kreilgaard, M. and Velschow, S. (2003): Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol. Biochem. Behav., <b>75<\/b>, 133-140.","DOI":"10.1016\/S0091-3057(03)00042-X"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Sasaki, H., Sato, H., Kuriyama-Matsumura, K., Sato, K., Maebara, K., Wang, H., Tamba, M., Itoh, K., Yamamoto, M. and Bannai, S. (2002): Electrophile response element-mediated induction of the cystine\/glutamate exchange transporter gene expression. J. Biol. Chem., <b>277<\/b>, 44765-44771.","DOI":"10.1074\/jbc.M208704200"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Sassa, S. (2006): Biological implications of heme metabolism. J. Clin. Biochem. Nutr., <b>38<\/b>, 138-155.","DOI":"10.3164\/jcbn.38.138"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Seeman, M.V. (2020): Men and women respond differently to antipsychotic drugs. Neuropharmacology, <b>163<\/b>, 107631.","DOI":"10.1016\/j.neuropharm.2019.05.008"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Shertzer, H.G., Kendig, E.L., Nasrallah, H.A., Johansson, E. and Genter, M.B. (2010): Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole. Int. J. Obes., <b>34<\/b>, 970-979.","DOI":"10.1038\/ijo.2009.291"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Siow, R.C., Sato, H., Leake, D.S., Pearson, J.D., Bannai, S. and Mann, G.E. (1998): Vitamin C protects human arterial smooth muscle cells against atherogenic lipoproteins: effects of antioxidant vitamins C and E on oxidized LDL-induced adaptive increases in cystine transport and glutathione. Arterioscler. Thromb. Vasc. Biol., <b>18<\/b>, 1662-1670.","DOI":"10.1161\/01.ATV.18.10.1662"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Solis, W.A., Dalton, T.P., Dieter, M.Z., Freshwater, S., Harrer, J.M., He, L., Shertzer, H.G. and Nebert, D.W. (2002): Glutamate-cysteine ligase modifier subunit: mouse Gclm gene structure and regulation by agents that cause oxidative stress. Biochem. Pharmacol., <b>63<\/b>, 1739-1754.","DOI":"10.1016\/S0006-2952(02)00897-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Suzuki, Y., Sugai, T., Ono, S., Sawamura, K., Fukui, N., Watanabe, J., Tsuneyama, N., Saito, M. and Someya, T. (2014): Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. Psychiatry Clin. Neurosci., <b>68<\/b>, 353-356.","DOI":"10.1111\/pcn.12136"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Taylor, D.M. and McAskill, R. (2000): Atypical antipsychotics and weight gain--a systematic review. Acta Psychiatr. Scand., <b>101<\/b>, 416-432.","DOI":"10.1034\/j.1600-0447.2000.101006416.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Ray, W.A., Chung, C.P., Murray, K.T., Hall, K. and Stein, C.M. (2009): Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med., <b>360<\/b>, 225-235.","DOI":"10.1056\/NEJMoa0806994"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Wirshing, D.A., Wirshing, W.C., Kysar, L., Berisford, M.A., Goldstein, D., Pashdag, J., Mintz, J. and Marder, S.R. (1999): Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry, <b>60<\/b>, 358-363.","DOI":"10.4088\/JCP.v60n0602"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Yagishita, Y., Uruno, A., Fukutomi, T., Saito, R., Saigusa, D., Pi, J., Fukamizu, A., Sugiyama, F., Takahashi, S. and Yamamoto, M. (2017): Nrf2 improves leptin and insulin resistance provoked by hypothalamic oxidative stress. Cell Rep., <b>18<\/b>, 2030-2044.","DOI":"10.1016\/j.celrep.2017.01.064"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/48\/4\/48_191\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:55:11Z","timestamp":1715316911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/48\/4\/48_191\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.48.191","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}